Phenylpropionic Acid Enantiomer Separation for Predictable PPAR Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing compounds with racemic mixtures of 2-[(2-(4-fluorobenzoyl)phenyl)amino]-3-[(4-(2-carbazole-ethoxy)phenyl)]propionic acid do not account for potential differences in pharmacological activities between enantiomers, which can lead to unpredictable physiological effects and toxicity.
Innovation Solution
Separation and study of the (-)-enantiomer of 2-[(2-(4-fluorobenzoyl)phenyl)amino]-3-[(4-(2-carbazole-ethoxy)phenyl)]propionic acid, which selectively activates PPAR-α, PPAR-γ, and PPAR-δ, and its pharmaceutically acceptable salts are prepared and studied for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If racemic mixture is used, then manufacturing complexity is reduced, but pharmacological activity and safety are unpredictable
Solution Approach 1:
The racemic mixture is segmented into individual enantiomers through chiral resolution. The patent separates the racemic mixture into (-)-enantiomer and (+)-enantiomer using chiral chromatography or diastereomeric salt formation, allowing each enantiomer to be evaluated independently for pharmacological activity and safety profile.
Solution Approach 2:
The harmful or less active enantiomer is extracted and removed from the mixture. The patent identifies that the (-)-enantiomer possesses the desired PPAR activation activity while the (+)-enantiomer shows reduced activity or potential adverse effects, leading to isolation and purification of the active (-)-enantiomer for therapeutic use.
2Reliability
If enantiomer separation is performed, then pharmacological activity and safety are improved, but manufacturing complexity increases
Solution Approach 1:
A chiral resolving agent or chiral stationary phase is introduced as an intermediary to facilitate enantiomer separation. The patent employs chiral auxiliaries or chiral chromatography media that temporarily interact with the enantiomers, enabling their separation based on differential binding affinities, after which the resolving agent is removed.
Solution Approach 2:
The separation process exploits parameter changes in the chiral environment. By changing conditions such as mobile phase composition, stationary phase chirality, or temperature during chromatography, the patent optimizes the resolution between enantiomers, achieving baseline separation while managing process complexity.
3Ease of operation
If racemic mixture is administered, then dosage is simplified, but toxic side effects may increase
Solution Approach 1:
The patent converts the potential harm of unknown enantiomeric effects into benefit by systematically evaluating each enantiomer's safety profile. Through toxicological studies on separated enantiomers, the patent identifies the (-)-enantiomer as the safe and effective component, eliminating the risk associated with the other enantiomer while maintaining dosage simplicity in the purified form.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention discloses an enantiomeric compound (-)-2- [(2-(4-fluorobenzoyl)phenyl)amine] -3 - [(4-(2-carbazole-ethoxy)phenyl)]propionic acid as represented by formula (I), or a pharmaceutical salt thereof, and a manufacturing method of the compound and application of same. The enantiomeric compound demonstrates relatively better activation of RXR/PPAR-, RXR/PPAR- and RXR/PPAR-heterodimer expression and sugar reduction in a db/db mouse model compared to a (+)-enantiomer.